Autoimmunity as a Consequence of Immune Checkpoint Inhibitor Therapy: Challenges in Recognition and Management
Uma Thanarajasingam, M.D., Ph.D.
Lisa A. Kottschade, APRN, C.N.P. 

LEARNING OBJECTIVES
Upon conclusion of this activity, participants should be able to:

• Cite the rationale for the use of immune checkpoint inhibitors (ICIs) in cancer therapy
• Recognize the spectrum of autoimmune toxicities, the so called "immune-related adverse events" (irAEs) that occur as a consequence of ICI therapy
• Overview approach to, and unknowns in, the management of various irAEs

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.